About TRIUMEQ

TRIUMEQ is a prescription medication containing the active ingredients Dolutegravir sodium, Abacavir sulfate, and Lamivudine. It is used in combination with other medications to treat HIV-1 infection in adults and children 4 weeks of age and older.

Key Benefits & Uses

Treatment of HIV-1 infection in combination with other medications.
Reduction of viral load and improvement of immune function in HIV-1 infected individuals.
Prevention of HIV-1 disease progression and associated complications.

Active Ingredient & Action

Dolutegravir sodium, Abacavir sulfate, and Lamivudine work together to inhibit the replication of HIV-1 virus. Dolutegravir sodium is an integrase inhibitor that blocks the integration of viral DNA into the host cell's genome. Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcription of viral RNA into DNA. Lamivudine is also an NRTI that inhibits the replication of HIV-1 virus by blocking the reverse transcription of viral RNA into DNA.

Important Notes

TRIUMEQ should be used under the guidance of a healthcare professional. It is essential to follow the prescribed dosage and treatment regimen to achieve optimal results. Patients with a history of hypersensitivity reactions to Abacavir or other NRTIs should not use TRIUMEQ. Regular monitoring of viral load and CD4 cell count is recommended to assess the effectiveness of treatment.